XpresSpa Group Announces Rapid PCR Testing Option to Expedite COVID-19 Testing Results In Real Time for More Airline Passe...
March 29 2021 - 8:30AM
XpresSpa Group, Inc. (Nasdaq: XSPA), a health and
wellness company, will continue to expand
its rapid COVID-19 testing efforts by offering
travelers another option with a rapid PCR-based testing platform.
The addition will enable XpresCheck™ to increase the
availability of rapid
PCR–based COVID-19 tests at XpresCheck airport sites,
starting with pilots at John F. Kennedy International Airport
today and George Bush Intercontinental Airport in Houston next
week.
XpresCheck will be offering the Accula
SARS-CoV-2 Test from Thermo Fisher Scientific. The testing
protocol has received an Emergency Use Authorization from the U.S.
Food and Drug Administration (FDA) and provides results in 30
minutes. XpresCheck is committed to helping protect
America’s airports and the health of everyone who works within
or passes through them with fast, accurate COVID-19 testing right
at the airport.
Doug Satzman, XpresSpa CEO said,
“PCR testing continues to be the key that unlocks access to more
travel destinations, so we are pleased to bring another convenient
rapid PCR test for travelers to get test results back at the
airport versus waiting for days. We are proud to be playing our
part in supporting the return of air travel to pre-pandemic levels
by making sure both airport employees and travelers feel safe and
confident when they come to the airport.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is
a leading global health and wellness holding
company. XpresSpa Group’s core asset, XpresSpa, is a
leading airport retailer of spa services and related health and
wellness products, with 45 locations in 23 airports globally.
Through its XpresTest, Inc. subsidiary, the Company
provides COVID-19 screening and testing under the XpresCheck™
brand at eleven locations in nine
airports: Boston Logan International
Airport (2), Denver International Airport, Dulles
International Airport, JFK International Airport, Newark
Liberty International Airport (2), Phoenix Sky Harbor
International Airport, Reagan National Airport, Salt Lake City
International Airport, and Seattle-Tacoma International Airport. To
learn more about XpresSpa Group,
visit: www.XpresSpaGroup.com.
Twitter: @xprescheck and
Instagram: @realxprescheck
Forward-Looking Statements
This press release may contain "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, and Section 21E of the Securities Exchange Act of 1934.
These include statements preceded by, followed by or that otherwise
include the words "believes," "expects," "anticipates,"
"estimates," "projects," "intends," "should," "seeks," "future,"
"continue," or the negative of such terms, or other comparable
terminology. In particular, these statements include, without
limitation, statements about our expectations relating to our
new XpresCheck™ concept, being able to expand testing to other
communicable diseases as well as administer vaccinations for the
seasonal flu, our positioning to be part of the national rollout of
various COVID-19 vaccinations as they become available, the degree
to which our public testing model assists passengers meet testing
requirements in select states and countries, our ability to
identify and gain access to the latest and best COVID-19 testing
methodologies and equipment, and our ability further expand our
initial sites and our overall ability to manage the regulatory
challenges associated with this business line. Forward-looking
statements relating to expectations about future results or events
are based upon information available to XpresSpa Group as
of today's date and are not guarantees of the future performance of
the company, and actual results may vary materially from the
results and expectations discussed. Additional information
concerning these and other risks is contained
in XpresSpa Group’s most recently filed Annual Report on
Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on
Form 8-K and other Securities and Exchange Commission filings. All
subsequent written and oral forward-looking statements
concerning XpresSpa Group, or other matters and
attributable to XpresSpa Group or any person acting on
its behalf are expressly qualified in their entirety by the
cautionary statements above. XpresSpa Group does not
undertake any obligation to publicly update any of these
forward-looking statements to reflect events or circumstances that
may arise after the date hereof.
The Accula SARS-CoV-2 Test has not been FDA
cleared or approved; it has been authorized by FDA under an EUA for
use by CLIA-certified laboratories that meet requirements to
perform high, moderate or waived complexity tests. It is also
authorized for use at the Point of Care (POC), i.e., in patient
care settings operating under a CLIA Certificate of Waiver,
Certificate of Compliance, or Certificate of Accreditation. This
test has been authorized only for the detection of nucleic acid
from SARS-CoV-2, not for any other viruses or pathogens. The Accula
SARS-CoV-2 Test is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostic tests for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.
§360bbb-3(b)(1), unless the authorization is terminated or revoked
sooner.
Investor Relations:ICRRaphael
Grossir@xpresspagroup.com (203) 682-8253
Media:Julie FergusonJulie@jfprmedia.com(312) 385-0098
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Apr 2024 to May 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From May 2023 to May 2024